Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

1.

Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration.

Abo Y, Zannou Djimon M, Messou E, Balestre E, Kouakou M, Akakpo J, Ahouada C, de Rekeneire N, Dabis F, Lewden C, Minga A; IeDEA West Africa Collaboration.

BMC Infect Dis. 2015 Apr 9;15:176. doi: 10.1186/s12879-015-0910-3.

2.

Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.

Orne-Gliemann J, Larmarange J, Boyer S, Iwuji C, McGrath N, Bärnighausen T, Zuma T, Dray-Spira R, Spire B, Rochat T, Lert F, Imrie J; ANRS 12249 TasP Group.

BMC Public Health. 2015 Mar 1;15:209. doi: 10.1186/s12889-015-1344-y.

3.

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Côte d'Ivoire.

Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, Eholie SP, Maylin S, Delaugerre C, Zoulim F, Girard PM, Lacombe K; ANRS 12240 VarBVA study.

Antivir Ther. 2015 Apr 8. doi: 10.3851/IMP2959. [Epub ahead of print]

PMID:
25852125
4.

Favipiravir for children with Ebola.

Bouazza N, Treluyer JM, Foissac F, Mentré F, Taburet AM, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P.

Lancet. 2015 Feb 14;385(9968):603-4. doi: 10.1016/S0140-6736(15)60232-X. No abstract available.

PMID:
25706078
5.

Dose regimen of favipiravir for Ebola virus disease.

Mentré F, Taburet AM, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D.

Lancet Infect Dis. 2015 Feb;15(2):150-1. doi: 10.1016/S1473-3099(14)71047-3. Epub 2014 Nov 28. No abstract available.

PMID:
25435054
6.

Missed opportunities for early access to care of HIV-infected infants in Burkina Faso.

Coulibaly M, Meda N, Yonaba C, Ouedraogo S, Congo M, Barry M, Thio E, Siribié I, Koueta F, Ye D, Kam L, Blanche S, Van De Perre P, Leroy V; MONOD Study Group ANRS 12206.

PLoS One. 2014 Oct 31;9(10):e111240. doi: 10.1371/journal.pone.0111240. eCollection 2014.

7.

The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.

Ross E, Tanser F, Pei P, Newell ML, Losina E, Thiebaut R, Weinstein M, Freedberg K, Anglaret X, Scott C, Dabis F, Walensky R.

HIV Clin Trials. 2014 Sep-Oct;15(5):185-98. doi: 10.1310/hct1505-185.

8.

Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.

Danel C, Kabran M, Inwoley A, Badje A, Herrmann JL, Moh R, Lecarrou J, Gabillard D, Ntakpe JB, Deschamps N, Ouattara E, Perronne C, Eholie S, Anglaret X.

PLoS One. 2014 Oct 16;9(10):e107245. doi: 10.1371/journal.pone.0107245. eCollection 2014.

9.

Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries.

Ballif M, Nhandu V, Wood R, Dusingize JC, Carter EJ, Cortes CP, McGowan CC, Diero L, Graber C, Renner L, Hawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Egger M, Fenner L; International epidemiological Databases to Evaluate AIDS (IeDEA).

Int J Tuberc Lung Dis. 2014 Nov;18(11):1327-36. doi: 10.5588/ijtld.14.0106.

PMID:
25299866
10.

Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire.

Jean K, Gabillard D, Moh R, Danel C, Desgrées-du-Loû A, N'takpe JB, Le Carrou J, Badjé A, Eholié S, Lert F, Anglaret X, Dray-Spira R.

J Int AIDS Soc. 2014 Jun 30;17:18977. doi: 10.7448/IAS.17.1.18977. eCollection 2014.

11.

Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa.

Ndondoki C, Dicko F, Ahuatchi Coffie P, Kassi Eboua T, Ekouevi DK, Kouadio K, Edmond Aka A, Malateste K, Dabis F, Amani-Bosse C, Toure P, Leroy V; Paediatric IeDEA West African Working Group.

J Int AIDS Soc. 2014 Jun 2;17:18737. doi: 10.7448/IAS.17.1.18737. eCollection 2014.

12.

Commentary: Antiretroviral therapy initiation criteria in low resource settings--from 'when to start' to 'when not to start'.

Eholie SP, Vella S, Anglaret X.

AIDS. 2014 Mar;28 Suppl 2:S101-4. doi: 10.1097/QAD.0000000000000237. No abstract available.

PMID:
24849468
13.

WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit?

Kouamé G, Danel C, Moh R, Badjé A, Jean K, N'takpe JB, Gabillard D, Le Carrou J, du Loû AD, Deschamps N, Eholie S, Anglaret X.

AIDS. 2014 Jun 19;28(10):1533-5. doi: 10.1097/QAD.0000000000000296.

PMID:
24804862
14.

Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children.

Desmonde S, Dicko F, Koueta F, Eboua T, Balestre E, Amani-Bosse C, Aka EA, Lawson-Evi K, Amorissani-Folquet M, Kouakou K, Koumakpai S, Renner L, Signaté Sy H, Leroy V; IeDEA West Africa Paediatric Collaboration.

AIDS. 2014 Jul 17;28(11):1645-55. doi: 10.1097/QAD.0000000000000272.

15.

Reasons for hospitalization in HIV-infected children in West Africa.

Dicko F, Desmonde S, Koumakpai S, Dior-Mbodj H, Kouéta F, Baeta N, Koné N, Akakpo J, Signate Sy H, Ye D, Renner L, Lewden C, Leroy V; Pediatric IeDEA West Africa Working Group.

J Int AIDS Soc. 2014 Apr 22;17:18818. doi: 10.7448/IAS.17.1.18818. eCollection 2014.

16.

Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.

Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):294-302. doi: 10.1097/QAI.0000000000000166.

17.

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.

Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; ANRS 12 180 Reflate TB study group.

Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9. Erratum in: Lancet Infect Dis. 2014 Jun;14(6):448.

PMID:
24726095
18.

Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era.

Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, Akakpo J, Dabis F, Eholié SP; IeDEA West Africa Collaboration.

J Int AIDS Soc. 2014 Apr 7;17:18797. doi: 10.7448/IAS.17.1.18797. eCollection 2014.

19.

Genotypic resistance profiles of HIV-2-treated patients in West Africa.

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK; IeDEA West Africa Collaboration.

AIDS. 2014 May 15;28(8):1161-9. doi: 10.1097/QAD.0000000000000244.

20.

Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008.

Abo Y, Minga A, Menan H, Danel C, Ouassa T, Dohoun L, Bomisso G, Tanoh A, Messou E, Eholié S, Lewden C, Anglaret X.

BMC Infect Dis. 2013 Dec 27;13:607. doi: 10.1186/1471-2334-13-607.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk